shp2 inhibitory activity (BPS Bioscience)
BPS Bioscience is a verified supplier 
BPS Bioscience manufactures this product 
94
Structured Review
BPS Bioscience
shp2 inhibitory activity
Shp2 Inhibitory Activity, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shp2+inhibitory+activity/SHP-2+Assay+Buffer/pm41114692-457-1-27
Average 94 stars, based on 1 article reviews
Shp2 Inhibitory Activity, supplied by BPS Bioscience, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/shp2+inhibitory+activity/SHP-2+Assay+Buffer/pm41114692-457-1-27
Average 94 stars, based on 1 article reviews
shp2 inhibitory activity - by Bioz Stars,
2026-09
94/100 stars
Images
Related Articles
Activity Assay:Article Title: Discovery of Potent and Orally bioavailable Benzoazepinamine-Based SHP2 Allosteric Inhibitors for the Treatment of Inflammatory Diseases. Article Snippet: Src homology-2 (SH2) domain-containing phosphatase-2 (SHP2) plays a crucial role in multiple cellular processes and is implicated in various human diseases.. While most SHP2 inhibitors under development primarily target cancer, their potential in inflammatory diseases remains largely unexplored.. In this study, we identified a novel series of benzoazepinamine-based SHP2 allosteric inhibitors. Article Title: Design, Synthesis and Evaluation of Thioacetamide‐Tethered Thiadiazole‐1,2,4‐Triazole Hybrids as SHP2 Inhibitors for Cancer Therapy Article Snippet: Src homology-2 (SH2) domain-containing phosphatase-2 (SHP2), the first protooncogenic phosphatase is a key mediator in the development and progression of various cancers.. Several allosteric sites have been identified in SHP2, inhibitors of which are being developed.. In the current study, we have designed and synthesized a library of 21 thioacetamide-tethered thiadiazole-1,2,4-triazole hybrids (compounds 16–36) and evaluated their in vitro SHP2 inhibitory potential. Fluorescence:Article Title: Discovery of Potent and Orally bioavailable Benzoazepinamine-Based SHP2 Allosteric Inhibitors for the Treatment of Inflammatory Diseases. Article Snippet: Src homology-2 (SH2) domain-containing phosphatase-2 (SHP2) plays a crucial role in multiple cellular processes and is implicated in various human diseases.. While most SHP2 inhibitors under development primarily target cancer, their potential in inflammatory diseases remains largely unexplored.. In this study, we identified a novel series of benzoazepinamine-based SHP2 allosteric inhibitors. Incubation:Article Title: Discovery of Potent and Orally bioavailable Benzoazepinamine-Based SHP2 Allosteric Inhibitors for the Treatment of Inflammatory Diseases. Article Snippet: Src homology-2 (SH2) domain-containing phosphatase-2 (SHP2) plays a crucial role in multiple cellular processes and is implicated in various human diseases.. While most SHP2 inhibitors under development primarily target cancer, their potential in inflammatory diseases remains largely unexplored.. In this study, we identified a novel series of benzoazepinamine-based SHP2 allosteric inhibitors. Sequencing:Article Title: Discovery of Potent and Orally bioavailable Benzoazepinamine-Based SHP2 Allosteric Inhibitors for the Treatment of Inflammatory Diseases. Article Snippet: Src homology-2 (SH2) domain-containing phosphatase-2 (SHP2) plays a crucial role in multiple cellular processes and is implicated in various human diseases.. While most SHP2 inhibitors under development primarily target cancer, their potential in inflammatory diseases remains largely unexplored.. In this study, we identified a novel series of benzoazepinamine-based SHP2 allosteric inhibitors. In Vitro:Article Title: Design, Synthesis and Evaluation of Thioacetamide‐Tethered Thiadiazole‐1,2,4‐Triazole Hybrids as SHP2 Inhibitors for Cancer Therapy Article Snippet: Src homology-2 (SH2) domain-containing phosphatase-2 (SHP2), the first protooncogenic phosphatase is a key mediator in the development and progression of various cancers.. Several allosteric sites have been identified in SHP2, inhibitors of which are being developed.. In the current study, we have designed and synthesized a library of 21 thioacetamide-tethered thiadiazole-1,2,4-triazole hybrids (compounds 16–36) and evaluated their in vitro SHP2 inhibitory potential. Inhibition:Article Title: Design, Synthesis and Evaluation of Thioacetamide‐Tethered Thiadiazole‐1,2,4‐Triazole Hybrids as SHP2 Inhibitors for Cancer Therapy Article Snippet: Src homology-2 (SH2) domain-containing phosphatase-2 (SHP2), the first protooncogenic phosphatase is a key mediator in the development and progression of various cancers.. Several allosteric sites have been identified in SHP2, inhibitors of which are being developed.. In the current study, we have designed and synthesized a library of 21 thioacetamide-tethered thiadiazole-1,2,4-triazole hybrids (compounds 16–36) and evaluated their in vitro SHP2 inhibitory potential. Recombinant:Article Title: Design, Synthesis and Evaluation of Thioacetamide‐Tethered Thiadiazole‐1,2,4‐Triazole Hybrids as SHP2 Inhibitors for Cancer Therapy Article Snippet: Src homology-2 (SH2) domain-containing phosphatase-2 (SHP2), the first protooncogenic phosphatase is a key mediator in the development and progression of various cancers.. Several allosteric sites have been identified in SHP2, inhibitors of which are being developed.. In the current study, we have designed and synthesized a library of 21 thioacetamide-tethered thiadiazole-1,2,4-triazole hybrids (compounds 16–36) and evaluated their in vitro SHP2 inhibitory potential. Binding Assay:Article Title: Design, Synthesis and Evaluation of Thioacetamide‐Tethered Thiadiazole‐1,2,4‐Triazole Hybrids as SHP2 Inhibitors for Cancer Therapy Article Snippet: Src homology-2 (SH2) domain-containing phosphatase-2 (SHP2), the first protooncogenic phosphatase is a key mediator in the development and progression of various cancers.. Several allosteric sites have been identified in SHP2, inhibitors of which are being developed.. In the current study, we have designed and synthesized a library of 21 thioacetamide-tethered thiadiazole-1,2,4-triazole hybrids (compounds 16–36) and evaluated their in vitro SHP2 inhibitory potential. De-Phosphorylation Assay:Article Title: Design, Synthesis and Evaluation of Thioacetamide‐Tethered Thiadiazole‐1,2,4‐Triazole Hybrids as SHP2 Inhibitors for Cancer Therapy Article Snippet: Src homology-2 (SH2) domain-containing phosphatase-2 (SHP2), the first protooncogenic phosphatase is a key mediator in the development and progression of various cancers.. Several allosteric sites have been identified in SHP2, inhibitors of which are being developed.. In the current study, we have designed and synthesized a library of 21 thioacetamide-tethered thiadiazole-1,2,4-triazole hybrids (compounds 16–36) and evaluated their in vitro SHP2 inhibitory potential. |